Overview:

Summary

The industry analysis specialist, has released its new report, “Dry Eye Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global dry eye syndrome market. The report identifies the key trends shaping and driving the global dry eye syndrome market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global dry eye syndrome sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData forecasts the global dry eye syndrome therapeutics market to grow at 6.3% annually for the next seven years to reach $2.8 billion by 2017. It was valued at $1,858m in 2010. This significant growth is primarily attributed to increasing therapeutic options for the treatment of dry eye. In addition, the successful launch of some of the molecular targeted therapies, such as rebamipide and Remura (bromfenac) currently in NDA (New Drug Application) filing may significantly stimulate market growth in the near future. However, the low prescription rate and non-adherence to medication will continue to be a barrier for market growth.
GlobalData analyzed that the global Dry eye syndrome market is increasingly becoming more competitive. Balancing the pipeline with the current marketed products and expectations of patients and physicians, the pipeline is considered to be strong. The unmet need in Dry eye syndrome market is high and if a company wants to capture this unmet need, it will need to overcome the prevailing product weaknesses.

Scope

The scope of the report includes -
- Annualized global Dry eye syndrome market revenues data from 2005 to 2010, forecast forward for seven years to 2017.
- Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes anti inflammatory, mucin production enhancement agent, immunosuppressant, interleukin inhibitor, steroid hormone, receptor modulators, platelet aggregation inhibitor, mTOR inhibitor, metalloprotease inhibitor, NSAIDs, immune modulators, NGF mimetic and genesilencing.
- Analysis of the current and future market competition in the global Dry eye syndrome market. Key market players covered are Otsuka Pharmaceuticals, CanFite BioPharma, ISTA Pharmaceuticals, Pfizer and Alcon/Novartis.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with Dry eye syndrome

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Dry eye syndrome market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global Dry eye syndrome market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Dry eye syndrome market landscape? – Identify, understand and capitalize

Companies Mentioned

Otsuka Pharmaceuticals Co. Ltd.
CanFite BioPharma Ltd.
ISTA Pharmaceuticals
Pfizer Inc.
Alcon/Novartis

1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Introduction 6
2.1 Overview 6
2.2 Etiology 7
2.3 Epidemiology 8
2.4 Symptoms 8
2.5 Diagnosis 9
2.5.1 External Inspection 9
2.5.2 Slit Lamp Biomicroscopy 9
2.5.3 Schirmer Tests 9
2.5.4 Tear Osmolarity 9
2.6 Treatment and Management Pattern 9
2.7 GlobalData Pipeline Report Guidance 10
3 Dry Eye Therapeutics: Market Characterization 11
3.1 Overview 11
3.2 Dry Eye Syndrome Therapeutics Market Size 11
3.3 Dry Eye Syndrome Therapeutics Market Size (2005-2010) – Global 11
3.4 Dry Eye Syndrome Therapeutics Market Forecast (2010-2017)– Global 12
3.5 Dry Eye Therapeutics Market Size (2005-2010) – the US 13
3.6 Dry Eye Therapeutics Market Forecast (2010-2017) – the US 14
3.7 Dry Eye Therapeutics Market Size (2005-2010) – France 15
3.8 Dry Eye Therapeutics Market Forecast (2010-2017) – France 16
3.9 Dry Eye Therapeutics Market Size (2005-2010) – Germany 17
3.10 Dry Eye Therapeutics Market Forecast (2010-2017) – Germany 18
3.11 Dry Eye Therapeutics Market Size (2005-2010) – Italy 19
3.12 Dry Eye Therapeutics Market Forecast (2010-2017) – Italy 20
3.13 Dry Eye Therapeutics Market Size (2005-2010) – Spain 21
3.14 Dry Eye Therapeutics Market Forecast (2010-2017) – Spain 22
3.15 Dry Eye Therapeutics Market Size (2005-2010) – the UK 23
3.16 Dry Eye Therapeutics Market Forecast (2010-2017) – the UK 24
3.17 Dry Eye Therapeutics Market Size (2005-2010) – Japan 25
3.18 Dry Eye Therapeutics Market Forecast (2010-2017) – Japan 26
3.19 Drivers and Barriers 27
3.19.1 Drivers for the DES Therapeutics Market 27
3.19.2 Barriers for the DES Therapeutics market 27
3.20 Opportunity and Unmet Needs 28
3.21 Key Takeaway 29
4 Dry Eye Syndrome Therapeutics Market – Competitive Assessment 30
4.1 Overview 30
4.2 Strategic Competitor Assessment 30
4.3 Product Profile for the Major Marketed Products in the Dry Eye Syndrome Therapeutics Market 31
4.3.1 Overview 31
4.3.2 Restasis (0.05% cyclosporine ophthalmic emulsion) 31
4.3.3 Diquas (diquafosol tetrasodium ophthalmic solution, 3%) 32
4.4 Key Takeaway 33
5 Dry Eye Syndrome Therapeutics: Pipeline Assessment 34
5.1 Overview 34
5.2 Strategic Pipeline Assessment 34
5.3 Pipeline by Phases of Development 34
5.3.1 Phase III Pipeline 34
5.3.2 Phase II Pipeline 35
5.3.3 Phase I and IND Filing Pipeline 35
5.3.4 Preclinical Pipeline 36
5.4 Dry Eye Syndrome Therapeutics Market – Clinical Pipeline by Mechanism of Action 37
5.5 Technology Trends Analytic Framework 38
5.6 Promising Drugs Under Clinical Development 40
5.7 Profile for Promising Drugs 40
5.7.1 Rebamipide (OPC-12759E) 40
5.7.2 CF101 40
5.7.3 Remura (bromfenac) 41
5.7.4 Tasocitinib (CP-690550) 41
5.8 Key Takeaway 41
6 Dry Eye Syndrome Therapeutics: Clinical Trials Mapping 42
6.1 Clinical Trials by Region/Country 42
6.2 Clinical Trials by Phase 43
6.3 Clinical Trials by Trial Status 44
6.4 Prominent Sponsors 45
6.5 Key Companies Participating in Therapeutics Clinical Trials 47
7 Dry Eye Syndrome Therapeutics: Strategic Assessment 48
7.1 Key Events Impacting the Future Market 48
7.2 Future Market Competition Scenario 48
8 Dry Eye Syndrome: Future Players 50
8.1 Introduction 50
8.2 Company Profiles 50
8.2.1 Otsuka Pharmaceuticals Co. Ltd. 50
8.2.2 CanFite BioPharma Ltd. 52
8.2.3 ISTA Pharmaceuticals 53
8.2.4 Pfizer Inc. 54
8.2.5 Alcon/Novartis 56
8.3 Other Companies in the Dry Eye Syndrome Therapeutics Market 57
9 Dry Eye Therapeutics: Liscensing and Partnership Deals 60
10 Appendix 62
10.1 Market Definitions 62
10.2 Abbreviations 62
10.3 Research Methodology 63
10.3.1 Coverage 63
10.3.2 Secondary Research 63
10.3.3 Forecasting 64
10.3.4 Primary Research 67
10.3.5 Expert Panel Validation 67
10.4 Contact Us 67
10.5 Disclaimer 67
10.6 Bibliography 68

1.1 List of Tables
Table 1: Dry Eye Syndrome – Severity Grading Scheme 6
Table 2: Dry Eye Syndrome – Treatment Pattern 9
Table 3: Dry Eye Syndrome Therapeutics Market, Global, Revenue ($m), 2005-2010 11
Table 4: Dry Eye Syndrome Therapeutics Market, Global, Forecast ($m), 2010-2017 12
Table 5: Dry Eye Syndrome Therapeutics Market, the US, Revenue ($m), 2005-2010 13
Table 6: Dry Eye Syndrome Therapeutics Market, the US, Forecast ($m), 2010-2017 14
Table 7: Dry Eye Syndrome Therapeutics Market, France, Revenue ($m), 2005-2010 15
Table 8: Dry Eye Syndrome Therapeutics Market, France, Forecast ($m), 2010-2017 16
Table 9: Dry Eye Syndrome Therapeutics Market, Germany, Revenue ($m), 2005-2010 17
Table 10: Dry Eye Syndrome Therapeutics Market, Germany, Forecast ($m), 2010-2017 18
Table 11: Dry Eye Syndrome Therapeutics Market, Italy, Revenue ($m), 2005-2010 19
Table 12: Dry Eye Syndrome Therapeutics Market, Italy, Forecast ($m), 2010-2017 20
Table 13: Dry Eye Syndrome Therapeutics Market, Spain, Revenue ($m), 2005-2010 21
Table 14: Dry Eye Syndrome Therapeutics Market, Spain, Forecast ($m), 2010-2017 22
Table 15: Dry Eye Syndrome Therapeutics Market, the UK, Revenue ($m), 2005-2010 23
Table 16: Dry Eye Syndrome Therapeutics Market, the UK, Forecast ($m), 2010-2017 24
Table 17: Dry Eye Syndrome Therapeutics Market, Japan, Revenue ($m), 2005-2010 25
Table 18: Dry Eye Syndrome Therapeutics Market, Japan, Forecast ($m), 2010-2017 26
Table 19: Dry Eye Syndrome Therapeutics – Historical Sales of Restasis 31
Table 20: Major Marketed Product Comparison in the Dry Eye Syndrome Therapeutics Market, 2010 32
Table 21: Dry Eye Syndrome Therapeutics – Regulatory and Phase III Clinical Pipeline, 2010 34
Table 22: Dry Eye Syndrome Therapeutics – Phase II Clinical Pipeline, 2010 35
Table 23: Dry Eye Syndrome Therapeutics – Phase I and IND Filed Clinical Pipeline, 2010 35
Table 24: Dry Eye Syndrome Therapeutics – Pre-Clinical Pipeline, 2010 36
Table 25: Dry Eye Syndrome Therapeutics – Most Promising Drugs Under Clinical Development, 2010 40
Table 26: Dry Eye Syndrome Therapeutics Market, Clinical Trials by Region, 2010 42
Table 27: Dry Eye Syndrome Therapeutics Market, Global, Clinical Trials by Phase of Development, 2010 43
Table 28: Dry Eye Syndrome Therapeutics Market, Global, Clinical Trials by Trial Status, 2010 44
Table 29: Dry Eye Syndrome Therapeutics Market, Global, Clinical Trials by Prominent Sponsors, 2010 46
Table 30: Dry Eye Syndrome Therapeutics Market, Global, Clinical Trials by Lead Sponsors, 2010 47
Table 31: Otsuka Pharmaceuticals Co. Ltd – Ophthalmology Pipeline Products, 2010 51
Table 32: Otsuka Pharmaceuticals Co. Ltd – Dry Eye Syndrome Pipeline Products, 2010 51
Table 33: Otsuka Pharmaceuticals – Deals, 2010 51
Table 34: Can-Fite BioPharma Ltd – Dry Eye Pipeline Products, 2010 52
Table 35: Can-Fite BioPharma – Deals, 2010 52
Table 36: ISTA Pharmaceuticals – Ophthalmology Pipeline Products, 2010 53
Table 37: ISTA Pharmaceuticals – Dry Eye Syndrome Pipeline Products, 2010 53
Table 38: ISTA Pharmaceuticals – Deals, 2010 53
Table 39: Pfizer Pharmaceuticals – Ophthalmology Pipeline Products, 2010 54
Table 40: Pfizer Pharmaceuticals – Dry Eye Pipeline Products, 2010 54
Table 41: Pfizer – Deals, 2010 55
Table 42: Alcon Pharmaceuticals – Dry Eye Syndrome Pipeline Products, 2010 56
Table 43: Alcon/Novartis – Deals, 2010 56
Table 44: Dry Eye Syndrome Therapeutics Market – Future Players, 2010 57
Table 45: Dry Eye Syndrome Therapeutics, Global, Deals, 2010 60

1.2 List of Figures
Figure 1: Dry Eye Syndrome – Etiology and Pathophysiology 7
Figure 2: Dry Eye Syndrome – Disease Etiology 8
Figure 3: Dry Eye Syndrome Therapeutics Market, Global, Revenue ($m), 2005-2010 11
Figure 4: Dry Eye Syndrome Therapeutics Market, Global, Forecast ($m), 2010-2017 12
Figure 5: Dry Eye Syndrome Therapeutics Market, the US, Revenue ($m), 2005-2010 13
Figure 6: Dry Eye Syndrome Therapeutics Market, the US, Forecast ($m), 2010-2017 14
Figure 7: Dry Eye Syndrome Therapeutics Market, France, Revenue ($m), 2005-2010 15
Figure 8: Dry Eye Syndrome Therapeutics Market, France, Forecast ($m), 2010-2017 16
Figure 9: Dry Eye Syndrome Therapeutics Market, Germany, Revenue ($m), 2005-2010 17
Figure 10: Dry Eye Syndrome Therapeutics Market, Germany, Forecast ($m), 2010-2017 18
Figure 11: Dry Eye Syndrome Therapeutics Market, Italy, Revenue ($m), 2005-2010 19
Figure 12: Dry Eye Syndrome Therapeutics Market, Italy, Forecast ($m), 2010-2017 20
Figure 13: Dry Eye Syndrome Therapeutics Market, Spain, Revenue ($m), 2005-2010 21
Figure 14: Dry Eye Syndrome Therapeutics Market, Spain, Forecast ($m), 2010-2017 22
Figure 15: Dry Eye Syndrome Therapeutics Market, the UK, Revenue ($m), 2005-2010 23
Figure 16: Dry Eye Syndrome Therapeutics Market, the UK, Forecast ($m), 2010-2017 24
Figure 17: Dry Eye Syndrome Therapeutics Market, Japan, Revenue ($m), 2005-2010 25
Figure 18: Dry Eye Syndrome Therapeutics Market, Japan, Forecast ($m), 2010-2017 26
Figure 19: Opportunity and Unmet Need in the Dry Eye Syndrome Therapeutics Market, 2010 28
Figure 20: Strategic Competitor Assessment of the Major Marketed Products in Dry Eye Syndrome, 2010 30
Figure 21: Dry Eye Syndrome Therapeutics Pipeline by Phase of Clinical Development, 2010 34
Figure 22: Dry Eye Syndrome Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010 37
Figure 23: Technology Trends Analytic Framework of the Dry Eye Syndrome Therapeutics Pipeline, 2010 38
Figure 24: Technology Trends Analytic Framework of the Dry Eye Syndrome Therapeutics Pipeline – Description, 2010 39
Figure 25: Dry Eye Syndrome Therapeutics Market – Clinical Trials by Region, 2010 42
Figure 26: Dry Eye Syndrome Therapeutics Market, Global, Clinical Trials by Phase of Development, 2010 43
Figure 27: Dry Eye Syndrome Therapeutics Market, Global, Clinical Trials by Trial Status, 2010 44
Figure 28: Dry Eye Syndrome Therapeutics Market, Global, Clinical Trials by Overall Sponsors, 2010 45
Figure 29: Dry Eye Syndrome Therapeutics Market, Global, Clinical Trials by Prominent Sponsors, 2010 46
Figure 30: Dry Eye Syndrome Therapeutics Market, Global, Clinical Trials by Top Companies, 2010 47
Figure 31: Key Events Competition in the Dry Eye Syndrome Market, 2010 48
Figure 32: Implications for Future Market Competition in the Dry Eye Syndrome Market, 2010 48
Figure 33: Dry Eye Syndrome Therapeutics Market – Clinical Pipeline by Company, 2010 50
Figure 34: GlobalData Market Forecasting Model 66